ASPIRE BIOPHARMA HOLDINGS, INC.: 10-Q filed 2023-05-11

Name: ASPIRE BIOPHARMA HOLDINGS, INC.: 10-Q filed 2023-05-11
Creator: ASPIRE BIOPHARMA HOLDINGS, INC.

What ASPIRE BIOPHARMA HOLDINGS, INC. reported in its quarterly report filed 2023-05-11 (fiscal Q1 2023): 16 published measures, 33 facts as tagged in accession 0001410578-23-001031.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-05-11
Fiscal period: fiscal Q1 2023
Accession: 0001410578-23-001031 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ASPIRE BIOPHARMA HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-03-31	303,107,536	USD
At 2022-12-31	300,182,005	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-03-31	11,168,921	USD
At 2022-12-31	11,115,823	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-03-31	-10,262,466	USD
At 2022-12-31	-9,937,901	USD
At 2022-03-31	-9,049,381	USD
At 2021-12-31	-475	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	2,872,433	USD	90
2022-01-01 to 2022-03-31	-87,826	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-182,107	USD	90
2022-01-01 to 2022-03-31	-1,287,923	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	296,593,545	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-294,687,500	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-03-31	-10,263,185	USD
At 2022-12-31	-9,938,620	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-03-31	906,455	USD
At 2022-12-31	1,097,752	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-03-31	356,421	USD
At 2022-12-31	303,323	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	324,565	USD	90
2022-01-01 to 2022-03-31	109,219	USD	90

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-03-31	315,152	USD
At 2022-12-31	497,259	USD
At 2022-03-31	618,122	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-03-31	591,303	USD
At 2022-12-31	600,493	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	2,872,433	USD	90
2022-01-01 to 2022-03-31	-87,826	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	324,565	USD	90
2022-01-01 to 2022-03-31	109,219	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	3,196,998	USD	90
2022-01-01 to 2022-03-31	21,393	USD	90

Inspect the source

Entity: ASPIRE BIOPHARMA HOLDINGS, INC. / CIK 0001847345
Captured: 2026-09-21T17:32:16.061Z
SEC response SHA-256: 40d6d0e6731934d6542812e865819d815a2e8f7284c4e26de8ab491caca2a549

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001847345.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))